Prescribing trends in treatment-resistant schizophrenia

References

• Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–448. doi: 10.1146/annurev-clinpsy-032813-153657
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–378. doi: 10.3109/15622975.2012.696143
   PubMed Web of Science ®Google Scholar
• Kennedy JL, Altar CA, Taylor DL, et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63–76. doi: 10.1097/YIC.0b013e32836508e6
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. FOCUS. 2012;10(2):194–216. doi: 10.1176/appi.focus.10.2.194
   Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of partients with schizophrenia. Am J Psychiatry. 2004;161(2 SUPPL.):1–56.
   PubMed Web of Science ®Google Scholar
• Kane JM. Treatment-resistant schizophrenic patients. J Clin Psychiatry. 1996;57:35–40.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Remington G, Mulsant BH, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012;197(1):1–6. doi: 10.1016/j.psychres.2012.02.013
   PubMed Web of Science ®Google Scholar
• Lee J, Takeuchi H, Fervaha G, et al. Erratum: subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms (Can J Psychiatry (2015) 60: 11 (515-522) DOI 10.1177/070674371506001107). Can J Psychiatry. 2016;61(3):196. doi: 10.1177/0706743716629440
   Web of Science ®Google Scholar
• Royal College of Psychiatrists. Consensus statement on high-dose antipsychotic medication (CR190). London: Royal College of Psychiatrists; 2014.
   Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. doi: 10.1016/S0140-6736(08)61764-X
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. doi: 10.1016/S0140-6736(13)60733-3
   PubMed Web of Science ®Google Scholar
• Galling B, Roldán A, Hagi K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017;16(1):77–89. doi: 10.1002/wps.20387
   PubMed Web of Science ®Google Scholar
• Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2008;35(2):443–457. doi: 10.1093/schbul/sbn018
   Web of Science ®Google Scholar
• Ceylan D, Yeşilyurt S, Akdede Bb, et al. Şizofreni tedavisinde çoklu antipsikotik kullanımının belirtiler, yan etkiler ve yaşam niteliği ile ilişkisi. Anadolu Psikiyatri Derg 2016; 17(6):433–444. doi: 10.5455/apd.211571
   Web of Science ®Google Scholar
• Karslioglu EH, Ozalp E, Sahiner IV, et al. Does combined antipsychotic treatment provide better control on symptoms in patients with schizophrenia than the monotherapy? Klinik Psikofarmakoloji Bülteni – Bull Clin Psychopharmacol. 2016;26(1):39–47. doi: 10.5455/bcp.20150629110950
   Web of Science ®Google Scholar
• Ozalmete OA, Ceylan ME, Ozalmete O, et al. Antipsychotic polypharmacy in schizophrenic inpatients/Yatan sizofreni hastalarinda coklu antipsikotik kullanimi. Arch Neuropsychiatry. 2010;47(1):23–29.
   Google Scholar
• Ensari H, Ceylan ME, Kılınç E, et al. Quality assessment of psychopharmacological treatment in mental health hospitals in Turkey. Klinik Psikofarmakoloji Bulteni – Bull Clin Psychopharmacol. 2004;14(2):68–78.
   Google Scholar
• SPSS I. IBM SPSS statistics for windows, version 20.0. New York (NY): IBM Corp; 2011.
   Google Scholar
• Kreyenbuhl J, Marcus SC, West JC, et al. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv. 2007;58(7):983–990. doi: 10.1176/ps.2007.58.7.983
   PubMed Web of Science ®Google Scholar
• Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004;65(10):1377–1388. doi: 10.4088/JCP.v65n1013
   PubMed Web of Science ®Google Scholar
• Howes OD, Vergunst F, Gee S, et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201(6):481–485. doi: 10.1192/bjp.bp.111.105833
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl J, Valenstein M, McCarthy JF, et al. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res. 2006;84(1):90–99. doi: 10.1016/j.schres.2006.02.023
   PubMed Web of Science ®Google Scholar
• Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. Chichester: John Wiley & Sons; 2015.
   Google Scholar
• Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138(1):18–28. doi: 10.1016/j.schres.2012.03.018
   PubMed Web of Science ®Google Scholar
• Harrison J, Janlöv M, Wheeler AJ. Patterns of clozapine prescribing in a mental health service in New Zealand. Pharm World Sci. 2010;32(4):503–511. doi: 10.1007/s11096-010-9398-5
   PubMedGoogle Scholar
• Bachmann C, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37–51. doi: 10.1111/acps.12742
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Lam D, Tano DS, et al. The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009. Can J Psychiatry. 2011;56(10):630–634. doi: 10.1177/070674371105601009
   Web of Science ®Google Scholar
• Alessi-Severini S, Le Dorze J-A, Nguyen D, et al. Clozapine prescribing in a Canadian outpatient population. PloS One. 2013;8(12):e83539. doi: 10.1371/journal.pone.0083539
   PubMed Web of Science ®Google Scholar
• Downs J, Zinkler M. Clozapine: national review of postcode prescribing. Psychiatrist. 2007;31(10):384–387.
   Google Scholar
• Malalagama G, Bastiampillai T, Dhillon R. Clozapine use in Australia. Australas Psychiatry. 2011;19(2):175–175. doi: 10.3109/10398562.2010.525646
   Web of Science ®Google Scholar
• Cetin M. Clozaphobia: fear of prescribers of clozapine for treatment of schizophrenia. Klinik Psikofarmakoloji Bülteni – Bull Clin Psychopharmacol. 2014; 24:4, 295–301 doi: 10.5455/bcp.20141223052008
   Web of Science ®Google Scholar
• Cetin M, Kose S. An updated clozapine treatment guide against clozaphobic attitudes. J Mood Disorders. 2016;6(4):242–255. doi: 10.5455/jmood.20161230061411
   Web of Science ®Google Scholar
• Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17(7):1083–1093. doi: 10.1017/S1461145712000399
   PubMed Web of Science ®Google Scholar
• Katona L, Czobor P, Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary. Schizophr Res. 2014;152(1):246–254. doi: 10.1016/j.schres.2013.10.034
   PubMed Web of Science ®Google Scholar
• Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009;29(2):165. doi: 10.1097/JCP.0b013e31819a8dbe
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70(10):1348–1357. doi: 10.4088/JCP.09m05154yel
   PubMed Web of Science ®Google Scholar